LIQUIDIA CORP (LQDA)
Health Care · biotechnology · NASDAQ
A biopharmaceutical company revolutionizing treatment for pulmonary hypertension using its proprietary PRINT particle engineering technology and treprostinil-based therapies.
What LIQUIDIA CORP does
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of treatments for respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company commercializes YUTREPIA (treprostinil) inhalation powder and manages the commercialization of a generic treprostinil injection in partnership with Sandoz. It also utilizes its proprietary PRINT particle engineering technology to develop its pipeline, including the liposomal formulation L606.
Themes: pulmonary hypertension, drug delivery systems, respiratory disease treatments, particle engineering
Fundamentals
- Price$70.27 as of 2026-08-24 close
- Market cap$6.3B as of 2026-08-24
- 1-year return+161.8% 2025-08-22 close $26.84 → 2026-08-24 close $70.27
- P/E430.84 as of 2026-08-24
- Net margin+7.7% as of 2026-08-24
- Gross margin+91.8% as of 2026-08-24
- ROE+46.8% as of 2026-08-24
- Debt / equity1.64 as of 2026-08-24
- Revenue growth (YoY)+1031.2% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)+115.0% SEC XBRL
- Beta1.02 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How LQDA compares in its sector
- price-to-earnings ratiotop 10% 191 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
LQDA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
47.8 #932 of 1,704 scored · #164 of 240 in Health Care
Catalysts 64th: analysts have raised their average price target by 27.0% since the prior reading; volume and participation 54th: trading volume is about normal versus its 30-day average; weakest is trend 39th: it is trading 13.3% below its 50-day average, the short-term trend line.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How LIQUIDIA CORP looks technically
LIQUIDIA CORP (LQDA) is trading 41.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 390 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-06-16, breaking below its recent trading range. It is 26.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 41.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +41.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $79.15 | $79.15 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $48.67 | $48.67 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 93.61. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 390 trading days ago — a "golden cross", a bullish long-term signal | 390 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 23.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.9 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($68.05 to $93.61) — its "stochastic" reading is 2 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 2.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $93.61 | $93.61 |
|---|---|---|
| From the 52-week high | it is 26.7% below its 52-week high (its highest price of the past year) | -26.7% |
| Above the 52-week low | it is 224.4% above its 52-week low (its lowest price of the past year) | +224.4% |
| Below the 52-week high | it is 26.7% below its highest point of the past year | 26.7% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-16, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $93.61 (set on 2026-08-11) | $93.61 |
| Given back of the 52-week move | over the past year its closes ranged ($21.80 to $91.03), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $46.03 to $48.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.4% |
| From the all-time high | it is 26.7% below its all-time high | -26.7% |
| Nearest price level | it is trading 48.0% above a support level at $35.67 — a price it turned at twice since 2025-12-09, most recently on 2026-04-22. Since 2024-08-21 it has 8 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -48.0% |
| All-time low | its lowest closing price on record is $2.25 (set on 2021-08-06) | $2.25 |
| Above the all-time low | it is 2949.8% above its all-time low | +2,950% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.06 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.06 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $67.92 and $96.22 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $67.92 – $82.07 – $96.22 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (41.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 27.0% since the prior reading | +26.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.25 toward sell |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 2.4% below the previous close 1 session ago and has not traded back through the level it left behind at 75.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.4% |
| Gap filled | a 2.3% gap up opened on 2026-08-04 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it took 6 sessions to close | 7 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -8.91% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.5 percentage points (the stock lost 15.2% while the market gained 2.3%) | -17.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.6 percentage points (the stock gained 10.7% while the market gained 3.1%) | +7.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 93.2 percentage points (the stock gained 104.3% while the market gained 11.1%) | +93.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 130.9 percentage points (the stock gained 151.4% while the market gained 20.5%) | +130.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 21.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $54.15 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +26.7% |
|---|
Price levels it has turned at before
LQDA last closed at $68.62 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $35.67 | Support | 48.0% below the last close | turned there twice · 2025-12-09 to 2026-04-22 |
| $29.15 | Support | 57.5% below the last close | turned there three times · 2025-11-04 to 2026-02-26 |
| $24.98 | Support | 63.6% below the last close | turned there twice · 2025-10-08 to 2025-10-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $93.61.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently RAISED · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$107.75 range $90.00 – $130.00; median $109.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for LQDA
- Consensus EPS estimate$0.836 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of significant annual operating losses and accumulated deficit.","Uncertainty regarding sustained revenue generation from YUTREPIA and future product candidates.","Requirement for significant capital to fund clinical trials and commercialization infrastructure."]
What changed in the latest 10-Q
AI-assisted comparison of LQDA's 10-Q filed 2026-05-11 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-11): Net losses of $68.9 million for year ended December 31, 2025 reported
- Newer filing (2026-05-11): Accumulated deficit of $573.5 million as of March 31, 2026 reported
- Newer filing (2026-05-11): L606 pivotal study described as 'worldwide, placebo-controlled pivotal study for the treatment of PH-ILD'
- Newer filing (2026-05-11): Plans to conduct clinical studies for YUTREPIA to evaluate treatment of PH-COPD, IPF, PPF, and SSc-RP
- Newer filing (2026-05-11): Comparison period changed to 'three months ended March 31, 2026 as compared to the three months ended March 31, 2025'
- Newer filing (2026-05-11): Reference to 'Annual Report on Form 10-K for the fiscal year ended December 31, 2025'
- Newer filing (2026-05-11): 'Product Sales, Net' section added with statement that revenue began in June 2025 following May 23, 2025 FDA approval
- Newer filing (2026-05-11): 'Service Revenue, Net' section header added
- Removed:
- Older filing (2025-11-03): Net loss of $83.5 million for nine months ended September 30, 2025 removed
- Older filing (2025-11-03): Accumulated deficit of $640.9 million as of September 30, 2025 removed
- Older filing (2025-11-03): L606 described with 'planned pivotal study for the treatment of PH-ILD' removed
- Older filing (2025-11-03): Comparison period 'three and nine months ended September 30, 2025 as compared to the three and nine months ended September 30, 2024' removed
- Older filing (2025-11-03): Reference to 'Annual Report on Form 10-K for the fiscal year ended December 31, 2024' removed
- Older filing (2025-11-03): 'Recent Event' section describing October 27, 2025 Vectura License Agreement removed
- Older filing (2025-11-03): Details regarding Vectura License Agreement upfront payment of $2.0 million and milestone payments removed
- Reworded:
- Newer filing: 'PRINT technology' changed from older filing 'PRINT® technology' (trademark symbol removed)
- Newer filing: 'other marketed inhaled treprostinil therapies' changed from older 'currently marketed inhaled treprostinil therapies'
- Newer filing: 'commercialization in June 2025' changed from older 'began commercialization on June 2, 2025' (specific date removed)
- Newer filing: 'FDA approval on May 23, 2025' changed from older 'approved by the U.S. Food and Drug Administration ("FDA") on May 23, 2025' (slightly different phrasing in context)
- Newer filing: 'minimum cash covenants' reference date changed from 'as of September 30, 2025' to 'as of March 31, 2026'
- Newer filing: 'consolidated financial statements included in this Quarterly Report on Form 10-Q' changed from older 'these consolidated financial statements included in this Quarterly Report on Form 10-Q'
- Notes:
- The newer filing text appears truncated at the end of the 'Service Revenue, Net' section; full comparison of that section is not possible
- The older filing text is also truncated at the Vectura License Agreement section; full details of changes to that section cannot be assessed
Risk Factors
- Added:
- In newer filing (2026-05-11): Added 'future' before 'commercial demand' in manufacturing risk bullet - now reads 'meet future commercial demand' instead of 'meet commercial demand'
- Removed:
- In older filing (2025-11-03): 'which we develop' regarding future pumps - newer filing (2026-05-11) expands to 'which we and/or Sandoz develop'
- Reworded:
- Risk factor on profitability: Changed from 'our future profitability remains uncertain' (2025-11-03) to 'our ability to sustain profitability in the future remains uncertain' (2026-05-11)
- Risk factor on commercial operation: Changed from 'We may not be able to build or maintain a commercial operation' (2025-11-03) to 'We may not be able to scale or maintain our commercial operation' (2026-05-11)
- Risk factor on supply of future pumps: Changed from 'any future pumps that we develop' (2025-11-03) to 'any future pumps that we and/or Sandoz develop' (2026-05-11)
- Notes:
- Text appears truncated at end of both versions; comparison limited to available content
- Both filings contain identical introductory language and several risk factors are word-for-word identical
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 70 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($200269) — 2 selling insiders
- Last 90 days0 buys · 70 sells ($125M) — 12 selling insiders
- Last 180 days1 buy ($317894) · 115 sells ($178M) — 1 buying, 14 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-27. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about LQDA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding LQDA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,876,057
- Reported value $372,722,399
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
LQDA had 11,962,898 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
LQDA had 13.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.25 days to cover at the same settlement.
- Reported short interest (shares) 11,962,898
- Short interest (% of shares outstanding) 13.4%
- Prior settlement (shares) 12,333,107
- Reported change -3%
- Days to cover (reported) 8.25
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare LQDA vs…
LQDA ranks in…
Frequently asked questions
What does LIQUIDIA CORP (LQDA) do?
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of treatments for respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company commercializes YUTREPIA (treprostinil) inhalation powder and manages the commercialization of a generic treprostinil injection in partnership with Sandoz.
What sector is LIQUIDIA CORP (LQDA) in?
LIQUIDIA CORP (LQDA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are LIQUIDIA CORP's (LQDA) competitors?
Notable peers of LIQUIDIA CORP (LQDA) include United Therapeutics and United Therapeutics (Tyvaso). This peer set is informational only — not financial advice.
Is LIQUIDIA CORP (LQDA) overbought or oversold right now?
LIQUIDIA CORP (LQDA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on LQDA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.